Prothena Corporation plc

Direct answer

Prothena Corporation plc is publicly traded on NASDAQ under the ticker PRTA.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an...

Can you invest in Prothena Corporation plc?

Yes. Prothena Corporation plc is publicly traded on NASDAQ under the ticker PRTA.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Prothena Corporation plc

Detailed equity research is provided by MarketSnap.